We are a specialty pharmaceutical company applying formulation and development expertise, as well as our drug delivery technology, to the development, manufacture and marketing of bioequivalent pharmaceutical products, commonly referred to as “generics,” in addition to the development, manufacture and marketing of branded products. We operate in two segments, referred to as “Impax Generics” and “Impax Specialty Pharma.” The Impax Generics division includes our legacy Global Pharmaceuticals business as well as the generic businesses from our acquisition of Tower Holdings Inc. ("Tower") and its subsidiaries on March 9, 2015 (the "Tower Acquisition"). The Impax Specialty Pharma division includes our legacy Impax Pharmaceuticals business as well as the acquired business of Amedra Pharmaceuticals, LLC ("Amedra") from the Tower Acquisition. Impax Generics concentrates its efforts on generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are usually marketed under their established nonproprietary drug names rather than by a brand name. Impax Specialty Pharma utilizes its specialty sales force to market proprietary branded pharmaceutical products for the treatment of central nervous system (“CNS”) disorders and other select specialty segments. See “Item 15. Exhibits and Financial Statement Schedules - Notes to Consolidated Financial Statements— Note 20. Segment Information,” for financial information about our segments for the years ended December 31, 2017, 2016 and 2015.
Company profile
Ticker
IPXL
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Global Pharmaceutical Corp, Impax Laboratories Inc
SEC CIK
Corporate docs
IRS number
650403311
IPXL stock data
Latest filings (excl ownership)
SC TO-I/A
Issuer tender offer statement (amended)
7 Jun 18
10-Q
2018 Q1
Quarterly report
10 May 18
SC TO-I
Issuer tender offer statement
7 May 18
8-K
Entry into a Material Definitive Agreement
7 May 18
25-NSE
Exchange delisting
4 May 18
8-K
Amneal and Impax Receive FTC Clearance for Business Combination
30 Apr 18
10-K/A
2017 FY
Annual report (amended)
13 Apr 18
CT ORDER
Confidential treatment order
5 Apr 18
8-K
Submission of Matters to a Vote of Security Holders
27 Mar 18
425
Business combination disclosure
20 Mar 18
Latest ownership filings
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|